Key result
A single injection of SF@Rsg-Mn (optimal ratio 1/14) into adipose tissues sustainably released rosiglitazone over 30 days, improving body weight and metabolism in a diet-induced obesity mouse model.
Why the study?
Current antiobesity medications require frequent administration and exhibit limited efficacy alongside severe side effects.
Does a single injection of SF@Rsg-Mn improve body weight and metabolic parameters in a diet-induced obesity mouse model?
Does a single injection of SF@Rsg-Mn improve body weight and metabolic parameters in a diet-induced obesity mouse model?
A novel injectable fiber system delivering rosiglitazone and manganese tetroxide nanoparticles synergistically promotes adipose tissue browning and ROS scavenging, improving metabolic parameters in a diet-induced obesity mouse model.
Hypothesis-generating for sustained adipose-targeted delivery in obesity models; leaves open translation to human metabolic therapy.
Obesity is a primary risk factor for type 2 diabetes, cardiovascular diseases, cancer, and other chronic diseases. Current antiobesity medications need frequent administration and show limited efficacy with severe side effects. Herein, browning agent rosiglitazone (Rsg) and antioxidant manganese tetroxide nanoparticles (MnNPs, around 250 nm) are integrated into electrospun short fibers (SF@Rsg-Mn) with a 1.5 μm width and a 20 μm length. Upon injection into inguinal adipose tissues, SF@Rsg-Mn are well retained in the local depots to sustainably release Rsg in 30 days for adipose tissue browning, while MnNPs on the fiber surface continuously scavenge adipose reactive oxygen species (ROS) for an extended period of time. Synergistic inhibition of fat accumulation through ROS scavenging and white adipocyte browning has been demonstrated for the first time, and the optimal synergistic ratio of Rsg and MnNPs is determined to be 1/14 via combination index examination. SF@Rsg-Mn inhibit lipid accumulation through downregulation of adipogenic gene PPARγ while promoting energy expenditure through upregulation of brown-specific gene UCP1 and mitochondrial function gene COX7A1. In a diet-induced obesity mouse model, a single injection of SF@Rsg-Mn into inguinal adipose tissues has accomplished a synergistic effect on body weight loss, fat reduction, glucose, and lipid metabolic improvement while minimizing adverse effects on other tissues, thereby paving the way to efficacious, safe, and practical treatment of obesity.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2021) studied Obesity. SF@Rsg-Mn (rosiglitazone and manganese tetroxide nanoparticles in electrospun short fibers) was evaluated on Body weight loss, fat reduction, glucose, and lipid metabolic improvement. A single injection of SF@Rsg-Mn (optimal ratio 1/14) into adipose tissues sustainably released rosiglitazone over 30 days, improving body weight and metabolism in a diet-induced obesity mouse model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: